GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: September 4, 2002, 19:50:42 ; Search time 13.39 Seconds
(without alignments)
160.960 Million cell updates/sec

Title: US-09-530-935-1
Perfect score: 14
Sequence: 1 tttgnnnnnnnnnnn 14

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 1046268293 residues

Total number of hits satisfying chosen parameters: 2595212

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl:*
1: qb_ba:*
2: qb_htg:*
3: qb_in:*
4: qb_om:*
5: qb_ov:*
6: qb_pat:*
7: qb_ph:*
8: qb_pl:*
9: qb_pr:*
10: qb_ro:*
11: qb_sts:*
12: qb_sy:*
13: qb_un:*
14: qb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htgo_inv:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
		*				
c 1	6	42.9	15	6	AR033568	AR033568 Sequence
c 2	6	42.9	15	6	AR078071	AR078071 Sequence
c 3	6	42.9	15	6	AR098748	AR098748 Sequence
c 4	6	42.9	15	6	AR113490	AR113490 Sequence
c 5	6	42.9	15	6	AR131711	AR131711 Sequence
c 6	6	42.9	15	6	AX100916	AX100916 Sequence
c 7	6	42.9	15	6	BB058865	BB058865 N-tol pro
c 8	6	42.9	15	6	E35652	E35652 Deletion c
c 9	6	42.9	15	6	E35697	E35697 Deletion a
c 10	6	42.9	15	6	157797	157797 Sequence 33
11	6	42.9	16	6	AX152920	AX152920 Sequence
c 12	6	42.9	17	6	A05414	A05414 Synthetic o
c 13	6	42.9	17	6	A09621	A09621 oligonucleo
14	6	42.9	17	6	AR046419	AR046419 Sequence
c 15	6	42.9	17	6	AR057460	AR057460 Sequence
c 16	6	42.9	17	6	AR057625	AR057625 Sequence
c 17	6	42.9	17	6	AR057702	AR057702 Sequence
18	6	42.9	17	6	AR101677	AR101677 Sequence
c 19	6	42.9	17	6	AR115218	AR115218 Sequence
c 20	6	42.9	17	6	AR115383	AR115383 Sequence
c 21	6	42.9	17	6	AR115460	AR115460 Sequence
c 22	6	42.9	17	6	AX006618	AX006618 Sequence
c 23	6	42.9	17	6	AX143981	AX143981 Sequence
c 24	6	42.9	17	6	AX261111	AX261111 Sequence
25	6	42.9	17	6	AX264145	AX264145 Sequence
26	6	42.9	17	6	AX265019	AX265019 Sequence
c 27	6	42.9	17	6	AX265020	AX265020 Sequence
28	6	42.9	17	6	AX265023	AX265023 Sequence
c 29	6	42.9	17	6	AX265024	AX265024 Sequence
30	6	42.9	17	6	AX265027	AX265027 Sequence
c 31	6	42.9	17	6	AX265029	AX265029 Sequence
32	6	42.9	17	6	AX265031	AX265031 Sequence
c 33	6	42.9	17	6	AX265032	AX265032 Sequence
c 34	6	42.9	17	6	AX325793	AX325793 Sequence
35	6	42.9	17	6	AX325794	AX325794 Sequence
c 36	6	42.9	17	6	AX325905	AX325905 Sequence
37	6	42.9	17	6	AX325906	AX325906 Sequence
38	6	42.9	17	6	158471	158471 Sequence 12
39	6	42.9	18	6	AR095464	AR095464 Sequence
c 40	6	42.9	18	6	AR096389	AR096389 Sequence
c 41	6	42.9	18	6	AR147460	AR147460 Sequence
c 42	6	42.9	18	6	AX145342	AX145342 Sequence
c 43	6	42.9	18	6	AX153064	AX153064 Sequence
c 44	6	42.9	18	6	AX153074	AX153074 Sequence
45	6	42.9	18	6	BD000895	BD000895 Composite

ALIGNMENTS

RESULT 1
AR033568/c
LOCUS AR033568 15 bp DNA linear PAT 24-SEP-1999
DEFINITION Sequence 334 from patent US 5869253.
ACCESSION AR033568
VERSION AR033568.1 GI:5949173
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Draper,K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 5869253-A 334 09-FEB-1999;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
BASE COUNT 6 a 4 c 3 g 2 t
ORIGIN

Query Match 42.9%; Score 6; DB 6; Length 15;
Best Local Similarity 42.9%; Pred. No. 1e-06;

```
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           ||||          ||
Db      15 TTTGCATGATGGGG 2


RESULT   2
AR078071/c
LOCUS       AR078071                    15 bp    DNA     linear   PAT 31-AUG-2000
DEFINITION  Sequence 11 from patent US 5962273.
ACCESSION   AR078071
VERSION     AR078071.1  GI:3654842
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Burmowiez,G.P., Harris,J.M. and Yunson,K.Dilly.
  TITLE     Detection of Neisseria gonorrhoeae by amplification and detection
            of its nucleic acid
  JOURNAL   Patent: US 5962273-A 11 05-OCT 1999;
FEATURES             Location/Qualifiers
     source          1..15
                     /organism="unknown."
BASE COUNT         7 a        4 c        2 g        2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           |||          ||
Db      14 TTTGATGATGGGGG 1


RESULT   3
AR098738/c
LOCUS       AR098738                    15 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 13 from patent US 6077669.
ACCESSION   AR098738
VERSION     AR098738.1  GI:12808504
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Little,M.C. and Vonk,G.P.
  TITLE     Kit and method for fluorescence based detection assay
  JOURNAL   Patent: US 6077669-A 13 20-JUN-2000;
FEATURES             Location/Qualifiers
     source          1..15
                     /organism="unknown"
BASE COUNT         7 a        4 c        2 g        2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           |||          ||
Db      14 TTTGATGATGGGGG 1


RESULT   4
AR113890/c
LOCUS       AR113890                    15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 334 from patent US 6132966.
ACCESSION   AR113890
VERSION     AR113890.1  GI:14094712
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 6132966-A 334 17-OCT 2000;
FEATURES             Location/Qualifiers
     source          1..15
                     /organism="Unknown"
BASE COUNT         7 a        4 c        2 g        2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           |||          ||
Db      15 TTTGATGATGGGGG 2


RESULT   5
AR131711/c
LOCUS       AR131711                    15 bp    DNA     linear   PAT 2-MAY-2001
DEFINITION  Sequence 136 from patent US 6194150.
ACCESSION   AR131711
VERSION     AR131711.1  GI:14120614
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,E. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of c40
  JOURNAL   Patent: US 6194150-A 136 27-FEB 2001;
FEATURES             Location/Qualifiers
     source          1..15
                     /organism="unknown"
BASE COUNT         6 a        3 c        2 g        1 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           ||||          ||
Db      15 TTTGACTGATAACG 2


RESULT   6
AX100916/c
LOCUS       AX100916                    15 bp    DNA     linear   PAT 10-APR-2001
DEFINITION  Sequence 13 from Patent WO0121817.
ACCESSION   AX100916
VERSION     AX100916.1  GI:13019808
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Muyldermans,S., Silence,K., Steyaert,J. and Joosten,F.
  TITLE     Recombinant phages capable of entering host cells via specific
            interaction with an artificial receptor
  JOURNAL   Patent: WO 0121817-A 13 29-MAR-2001;
            Vlaams Interuniversitair Instituut voor Biotechnologie vz, v. (BE)
FEATURES             Location/Qualifiers
     source          1..15
```

```
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"
     misc_feature    1. .15
                     /note="primer"
BASE COUNT        5 a      6 c      2 g      2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGTCCGTGAACG 1


RESULT   7
BD005865/c
LOCUS       BD005865                  15 bp    DNA     linear   PAT 31-JAN 2002
DEFINITION  Novel probes for the detection of Mycobacteria
ACCESSION   BD005865
VERSION     BD005865.1  GI:18634236
KEYWORDS    JP 2001501825-A/76.
SOURCE      unidentified.
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stender,H., Lund,K. and Mollerup,T.A.
  TITLE     Novel probes for the detection of Mycobacteria
  JOURNAL   Patent: JP 2001501825-A 76 13-FEB-2001;
            DAKO AS
COMMENT     OS   Unidentified
            PN   JP 2001501825-A/76
            PD   13-FEB-2001
            PF   03-OCT-1997 JP 1998517095
            PR   04-OCT-1996 DK      1996/96 DK 31-JAN-1997 DK      117/97 DK
            05-MAY-1997 DK      0513/97
            PI   HENRIK STENDER,KAARE LUND,TINA ANDERSEN MOLLERUP PC
            C12Q1/68,C07K14/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism 'Unidentified'
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /db_xref "taxon:32644"
BASE COUNT        6 a      7 c      1 g      1 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGTGTGGAGTCG 1


RESULT   8
E35652/c
LOCUS       E35652                    15 bp    DNA     linear   PAT 07-FEB-2001
DEFINITION  Detection of Neisseria gonorrhoeae by amplifying and detecting
            nucleic acid of Neisseria gonorrhoeae.
ACCESSION   E35652
VERSION     E35652.1  GI:13019128
KEYWORDS    JP 1999225781-A/11.
SOURCE      unidentified.
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Jerrold,B.D.J. and Harris,K.D.Y.
  TITLE     Detection of Neisseria gonorrhoeae by amplifying and detecting
            nucleic acid of Neisseria gonorrhoeae
  JOURNAL   Patent: JP 1999225781-A 11 24-AUG-1999;
            BECTON DICKINSON & CO
COMMENT     OS   Artifical Sequence
            PN   JP 1999225781-A/11
            PD   24-AUG-1999
            PF   30-OCT-1998 JP 1998309591
            PR   04-NOV-1997 US      08/963946
            PI   JERROLD B DAMOWITSO,JAMES M HARRIS,KAREN DIRI YANSEN PC
            C12N15/09,C12N1/21,C12N15/31,C12N15/09,C12N15/09,C12N15/31,C12Q1/68,
            (C12Q1/68,C12R1:91);,C12N15/09,(C12N15/09,C12R1:91) CC
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artifical Sequence'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism "unidentified"
                     /db_xref "taxon:32644"
BASE COUNT        7 a      4 c      2 g      2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGATGATTTGCG 1


RESULT   9
E35697/c
LOCUS       E35697                    15 bp    DNA     linear   PAT 07-FEB-2001
DEFINITION  Detection assay with the use of fluorescence and kit therefor.
ACCESSION   E35697
VERSION     E35697.1  GI:13019169
KEYWORDS    JP 1999225799-A/13.
SOURCE      unidentified.
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Michael,C.L.G.G. and Vong.
  TITLE     Detection assay with the use of fluorescence and kit therefor
  JOURNAL   Patent: JP 1999225799-A 13 24-AUG-1999;
            BECTON DICKINSON & CO
COMMENT     OS   Artificial Sequence
            PN   JP 1999225799-A/13
            PD   24-AUG-1999
            PF   04-NOV-1998 JP 1998312790
            PR   04-NOV-1997 US      08/964020
            PI   MICHAEL G LITTLE,GREN P VONG
            C12Q1/68,C07K14/00
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism 'Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /db_xref "taxon:32644"
BASE COUNT        7 a      4 c      2 g      2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnnq 14
```

```
          ||||         ||
Db      11 TTTGATGATTTGCG 1


RESULT 10
157797/c
LOCUS       157797                    15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 334 from patent US 5610054.
ACCESSION   157797
VERSION     157797.1  GI:2482861
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Enzymatic RNA molecule targeted against Hepatitis C virus
  JOURNAL   Patent: US 5610054-A 334 11-MAR-1997;
FEATURES             Location/Qualifiers
     source          1..15
                     /organism="unknown"
BASE COUNT        6 a       4 c       3 g       2 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      15 TTTGCATGATGCCG 2


RESULT 11
AX142920
LOCUS       AX142920                  16 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 4138 from Patent WO0130362.
ACCESSION   AX142920
VERSION     AX142920.1  GI:14149230
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Robbins,J.M. and Fritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362 A 4138 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1..16
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /note="Hairpin ribozyme recognition site for cyclin B1"
BASE COUNT        0 a       3 c       7 g       6 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 16;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db       2 TTTGGTCTGGGTCG 15


RESULT 12
A05414/c
LOCUS       A05414                    17 bp    DNA     linear   PAT 12-APR-1994
DEFINITION  Synthetic oligonucleotide primer RuoetalBACK.
ACCESSION   A05414
VERSION     A05414.1  GI:512617
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   .
  JOURNAL   Patent: WO 9005144 A 38 17-MAY-1990;
FEATURES             Location/Qualifiers
     source          1..17
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
BASE COUNT        8 a       2 c       3 g       4 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGCATATTCACG 1


RESULT 13
A09621/c
LOCUS       A09621                    17 bp    DNA     linear   PAT 12-OCT-1995
DEFINITION  Oligonucleotide.
ACCESSION   A09621
VERSION     A09621.1  GI:490594
KEYWORDS    .
SOURCE      synthetic construct.
  ORGANISM  synthetic construct
            artificial sequence.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Winter,G.P., Guessow,D. and Ward,E.S.
  TITLE     Single domain ligands, receptors comprising said ligands, methods
            for their production, and use of said ligands and receptors
  JOURNAL   Patent: EP 0368684 A 38 16-MAY-1990;
            MEDICAL RESEARCH COUNCIL
FEATURES             Location/Qualifiers
     source          1..17
                     /organism="synthetic construct"
                     /db_xref="taxon:32630"
BASE COUNT        8 a       2 c       3 g       4 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGCATATTCACG 1


RESULT 14
AR046419
LOCUS       AR046419                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1212 from patent US 5817796.
ACCESSION   AR046419
VERSION     AR046419.1  GI:5967884
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     Class I ribozymes having 2'-5' linked adenylate residues
  JOURNAL   Patent: US 5817796 A 1212 06-OCT-1998;
```

```
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
BASE COUNT        4 a      1 c      6 g      6 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnq 14
           ||||         ||
Db       1 TTTGAGATATGACG 14


RESULT  15
AR057460/c
LOCUS       AR057460                 17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1664 from patent US 5837542.
ACCESSION   AR057460
VERSION     AR057460.1  GI:5983037
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542 A 1664 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
BASE COUNT        7 a      4 c      5 g      1 t
ORIGIN


  Query Match             42.9%;  Score 6;  DB 6;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e-06;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGTGATCCTCCG 1


Search completed: September  3, 2002, 23:53:40
Job time: 14398 sec
```

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: September 3, 2002, 21:01:32 ; Search time 202.22 Seconds
(without alignments)
118.865 Million cell updates/sec

Title: US-09-530-935-1
Perfect score: 14
Sequence: 1 tttgnnnnnnnncg 14

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/hold-geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	6	42.9	14	21	AA259890	Adenovirus minimal
	2	6	42.9	14	21	AA259891	Adenovirus minimal
	3	6	42.9	14	21	AA259894	Adenovirus minimal
	4	6	42.9	14	21	AA259895	Adenovirus minimal
c	5	6	42.9	15	17	AAX64642	Human B7-1 hammerh
c	6	6	42.9	15	20	AAX56323	Neisseria gonorrhe
c	7	6	42.9	15	20	AAX30272	Neisseria gonorrhe
	8	6	42.9	15	21	AA259897	Consensus adenovir
c	9	6	42.9	15	21	AA262723	Substrate for HH r
c	10	6	42.9	15	22	AAF57499	pBAD vpt. Vector a
c	11	6	42.9	15	22	AAF46300	IGFBP2 oligonucleo
c	12	6	42.9	15	22	AAF46301	IGFBP2 oligonucleo
c	13	6	42.9	15	22	AAF47804	IGFBP3 oligonucleo
c	14	6	42.9	15	22	AAF47805	IGFBP3 oligonucleo
	15	6	42.9	15	22	AAF49895	IGF-I oligonucleot
	16	6	42.9	15	22	AAF49896	IGF-I oligonucleot
	17	6	42.9	15	22	AAF52544	IGF-I oligonucleot
	18	6	42.9	15	22	AAF52545	IGF-I oligonucleot
	19	6	42.9	15	22	AAF52808	IGF-I oligonucleot
	20	6	42.9	15	22	AAF52809	IGF I oligonucleot
c	21	6	42.9	16	13	AAQ21918	TEG-terminated exo
	22	6	42.9	16	19	AAT91222	Hairpin ribozyme r
	23	6	42.9	16	21	AAA86548	Cyclin B1 hairpin
	24	6	42.9	16	22	AAH61714	Cyclin B1 hairpin/
c	25	6	42.9	17	16	AAT53639	Rat ICAM hammerhea
c	26	6	42.9	17	16	AAT53696	Rat ICAM hammerhea
c	27	6	42.9	17	16	AAT53489	Rat ICAM hammerhea
	28	6	42.9	17	17	AAT81651	Human c-myb hammer
c	29	6	42.9	17	18	AAX72753	Mouse flk-1 VEGF r
c	30	6	42.9	17	18	AAX72754	Mouse flk-1 VEGF r
	31	6	42.9	17	18	AAX71472	Human KDR VEGF rec
	32	6	42.9	17	18	AAX69246	Human flt1 VEGF re
	33	6	42.9	17	19	AAV96670	Potato citrate syn
	34	6	42.9	17	20	AAA18878	Human IIE-2 substr
	35	6	42.9	17	20	AAY80251	Human BRCA1 wild t
c	36	6	42.9	17	20	AAV93663	Human B-raf substr
c	37	6	42.9	17	20	AAV92584	Human A-Raf substr
	38	6	42.9	17	20	AAV90956	Human C-raf target
c	39	6	42.9	17	21	AAC71979	Single nucleotide
c	40	6	42.9	17	21	AAC71985	Single nucleotide
c	41	6	42.9	17	21	AAA80154	Hepatitis B virus
	42	6	42.9	17	21	AAZ56918	MMCP-4 gene specif
c	43	6	42.9	17	21	AAZ15797	Nucleotide sequenc
c	44	6	42.9	17	21	AAZ45960	Human presenilin 2
c	45	6	42.9	17	22	ABA78689	APC mutation corre

ALIGNMENTS

RESULT 1
AA259890
ID AA259890 standard; DNA; 14 BP
XX
AC AA259890;
XX
DT 08-MAY-2000 (first entry)
XX
DE Adenovirus minimal packaging element, A repeat A1
XX
KW Adenovirus; minimal packaging element; A repeat; repressor binding site;
KW DNA delivery; ds.
XX
OS Mastadenovirus.
XX
PN WO9953085-A2.
XX
PD 21-OCT-1999.
XX
PF 15-APR-1999; 99WO-US08294.
XX
PR 15-APR-1998; 98US-0081867.
PR 05-JUN-1998; 98US-0088321.
XX
PA (RYNY) UNIV NEW YORK STATE RES FOUND.
XX
PI Hearing P, Schmid SI, Ostapchuk PH, Erturk E;
XX
DR WPI; 2000-052657/04.
XX
PT Regulating adenoviral packaging by incorporation of repressor binding
PT sites that allow selective suppression of packaging, used for gene

```
PT   therapy
XX
PS   Disclosure; Page 15; 71pp; English.
XX
CC   The invention relates to the regulation of adenoviral packaging.
CC   The method of the invention comprises propagating an adenoviral
CC   vector containing a repressor binding site, in the absence of the
CC   repressor. After propagation, vector packaging is repressed by the
CC   appropriate repressor protein. The invention also encompasses an
CC   adenoviral vector that includes an adenoviral packaging sequence
CC   containing several C/EBP IP (chicken ovalbumin upstream promoter
CC   transcription factor) binding sites (AAZ59919). Adenoviral vectors
CC   containing repressor binding sites are used for DNA delivery, e.g., for
CC   expression of a therapeutic protein, in genetic immunisation, or to
CC   produce antiviral DNA or antisense RNA. Typical heterologous genes that
CC   can be expressed include those for interleukin-2, alpha1-antitrypsin,
CC   cystic fibrosis transmembrane conductance regulator and coagulation
CC   factor VIII. These vectors have very large capacity (up to 36 kb) for
CC   foreign DNA and minimise the risk of generating replication competent
CC   virus (since vector and helper virus can be designed such that they
CC   have no overlapping packaging sequences that might permit homologous
CC   recombination). The presence of the repressor binding site allows
CC   selective inhibition of virion production (i.e., packaging of the vector
CC   in presence of another). Sequences AAZ59890 Z59896 represent adenovirus
CC   minimal packaging elements, designated A repeats A1 AV11, and AAZ59897
CC   represents a consensus of these A repeats.
XX
SQ   Sequence 14 BP; 2 A; 3 C; 5 G; 4 T; 0 other;


  Query Match             42.9%;  Score 6;  DB 21;  Length 14;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 TTTGAAGAAAAAAG 14
           |||| |     |
Db       1 TTTGAGCTAACCAG 14


RESULT   2
AAZ59891
ID   AAZ59891 standard; DNA; 14 BP.
XX
AC   AAZ59891;
XX
DT   08-MAY-2000  (first entry)
XX
DE   Adenovirus minimal packaging element, A repeat A11.
XX
KW   Adenovirus; minimal packaging element; A repeat; repressor binding site;
KW   DNA delivery; ds.
XX
OS   Mastadenovirus.
XX
PN   WO9963085-A2.
XX
PD   21-OCT-1999.
XX
PF   15-APR-1999;  99WO-US08294.
XX
PR   17-APR-1998;  98US-0082067.
PR   05-JUN-1998;  98US-0088421.
XX
PA   (UYNY ) UNIV NEW YORK STATE RES FOUND.
XX
PI   Bearing P, Schmid SI, Ostapchuk PB, Hearing E;
XX
DR   WPI; 2000-052657/04.
XX
PT   Regulating adenoviral packaging by incorporation of repressor binding
PT   sites that allow selective suppression of packaging, used for gene
PT   therapy
XX
PS   Disclosure; Page 15; 71pp; English.
XX
CC   The invention relates to the regulation of adenoviral packaging.
CC   The method of the invention comprises propagating an adenoviral
CC   vector containing a repressor binding site, in the absence of the
CC   repressor. After propagation, vector packaging is repressed by the
CC   appropriate repressor protein. The invention also encompasses an
CC   adenoviral vector that includes an adenoviral packaging sequence
CC   containing several C/EBP IP (chicken ovalbumin upstream promoter
CC   transcription factor) binding sites (AAZ59919). Adenoviral vectors
CC   containing repressor binding sites are used for DNA delivery, e.g., for
CC   expression of a therapeutic protein, in genetic immunisation, or to
CC   produce antiviral DNA or antisense RNA. Typical heterologous genes that
CC   can be expressed include those for interleukin-2, alpha1-antitrypsin,
CC   cystic fibrosis transmembrane conductance regulator and coagulation
CC   factor VIII. These vectors have very large capacity (up to 36 kb) for
CC   foreign DNA and minimise the risk of generating replication competent
CC   virus (since vector and helper virus can be designed such that they
CC   have no overlapping packaging sequences that might permit homologous
CC   recombination). The presence of the repressor binding site allows
CC   selective inhibition of virion production (i.e., packaging of the vector
CC   in presence of another). Sequences AAZ59890 Z59896 represent adenovirus
CC   minimal packaging elements, designated A repeats A1 AV11, and AAZ59897
CC   represents a consensus of these A repeats.
XX
SQ   Sequence 14 BP; 1 A; 3 C; 4 G; 4 T;    other;


  Query Match             42.9%;  Score 6;  DB 21;  Length 14;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 TTTGAAGAAAAAAG 14
           | | |     |
Db       1 TCTGAGCTAACCAG 14


RESULT   3
AAZ59894
ID   AAZ59894 standard; DNA; 11 BP.
XX
AC   AAZ59894;
XX
DT   08-MAY-2000  (first entry)
XX
DE   Adenovirus minimal packaging element, A repeat AV.
XX
KW   Adenovirus; minimal packaging element; A repeat; repressor binding site;
KW   DNA delivery; ds.
XX
OS   Mastadenovirus.
XX
PN   WO9963085-A2.
XX
PD   21-OCT-1999.
XX
PF   15-APR-1999;  99WO-US08294.
XX
PR   17-APR-1998;  98US-0082067.
PR   05-JUN-1998;  98US-0088421.
XX
PA   (UYNY ) UNIV NEW YORK STATE RES FOUND.
XX
PI   Bearing P, Schmid SI, Ostapchuk PB, Hearing E;
XX
DR   WPI; 2000-052657/04.
XX
PT   Regulating adenoviral packaging by incorporation of repressor binding
PT   sites that allow selective suppression of packaging, used for gene
PT   therapy
XX
PS   Disclosure; Page 15; 71pp; English.
XX
```

CC The invention relates to the regulation of adenoviral packaging.
CC The method of the invention comprises propagating an adenoviral
CC vector containing a repressor binding site, in the absence of the
CC repressor. After propagation, vector packaging is repressed by the
CC appropriate repressor protein. The invention also encompasses an
CC adenoviral vector that includes an adenoviral packaging sequence
CC containing several COUP-TF (chicken ovalbumin upstream promoter
CC transcription factor) binding sites (AAZ59919). Adenoviral vectors
CC containing repressor binding sites are used for DNA delivery, e.g., for
CC expression of a therapeutic protein; in genetic immunisation; or to
CC produce antiviral DNA or antisense RNA. Typical heterologous genes that
CC can be expressed include those for interleukin-2, alpha1-antitrypsin,
CC cystic fibrosis transmembrane conductance regulator and coagulation
CC factor VIII. These vectors have very large capacity (up to 36 kb) for
CC foreign DNA and minimise the risk of generating replication competent
CC virus (since vector and helper virus can be designed such that they
CC have no overlapping packaging sequences that might permit homologous
CC recombination). The presence of the repressor binding site allows
CC selective inhibition of virion production (i.e., packaging of one vector
CC in presence of another). Sequences AAZ59890-59896 represent adenovirus
CC minimal packaging elements, designated A repeats AI-AVII, and AAZ59897
CC represents a consensus of these A repeats.
XX
SQ Sequence 14 BP; 1 A; 3 C; 5 G; 5 T; 0 other;

Query Match 42.9%; Score 6; DB 21; Length 14;
Best Local Similarity 42.9%; Pred. No. 8.1e+04;
Matches 6; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttgnnnnnnnncg 14
|||| ||
Db 1 ttttgtctagggccg 14

RESULT 4
AAZ59895
ID AAZ59895 standard; DNA; 14 BP.
XX
AC AAZ59895;
XX
DT 08-MAY-2000 (first entry)
XX
DE Adenovirus minimal packaging element, A repeat AVI.
XX
KW Adenovirus; minimal packaging element; A repeat; repressor binding site;
KW DNA delivery; ds.
XX
OS Mastadenovirus.
XX
PN WO9953085-A2.
XX
PD 21-OCT-1999.
XX
PF 15-APR-1999; 99WO-US08294.
XX
PR 15-APR-1998; 98US-0081867.
PR 05-JUN-1998; 98US-0088421.
XX
PA (UYNY) UNIV NEW YORK STATE RES FOUND.
XX
PI Hearing P, Schmid SI, Ostapchuk PH, Erturk E;
XX
DR WPI; 2000-052653/04.
XX
PT Regulating adenoviral packaging by incorporation of repressor binding
PT sites that allow selective suppression of packaging, used for gene
PT therapy -
XX
PS Disclosure; Page 15; 71pp; English.
XX
CC The invention relates to the regulation of adenoviral packaging.
CC The method of the invention comprises propagating an adenoviral
CC vector containing a repressor binding site, in the absence of the
CC repressor. After propagation, vector packaging is repressed by the
CC appropriate repressor protein. The invention also encompasses an
CC adenoviral vector that includes an adenoviral packaging sequence
CC containing several COUP-TF (chicken ovalbumin upstream promoter
CC transcription factor) binding sites (AAZ59919). Adenoviral vectors
CC containing repressor binding sites are used for DNA delivery, e.g., for
CC expression of a therapeutic protein; in genetic immunisation; or to
CC produce antiviral DNA or antisense RNA. Typical heterologous genes that
CC can be expressed include those for interleukin-2, alpha1-antitrypsin,
CC cystic fibrosis transmembrane conductance regulator and coagulation
CC factor VIII. These vectors have very large capacity (up to 36 kb) for
CC foreign DNA and minimise the risk of generating replication competent
CC virus (since vector and helper virus can be designed such that they
CC have no overlapping packaging sequences that might permit homologous
CC recombination). The presence of the repressor binding site allows
CC selective inhibition of virion production (i.e., packaging of one vector
CC in presence of another). Sequences AAZ59890-59896 represent adenovirus
CC minimal packaging elements, designated A repeats AI-AVII, and AAZ59897
CC represents a consensus of these A repeats.
XX
SQ Sequence 14 BP; 2 A; 3 C; 3 G; 6 T; 0 other;

Query Match 42.9%; Score 6; DB 21; Length 14;
Best Local Similarity 42.9%; Pred. No. 8.1e+04;
Matches 6; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttgnnnnnnnncg 14
|||| ||
Db 1 ttttgaccgttaacg 14

RESULT 5
AAX64642/c
ID AAX64642 standard; RNA; 15 BP.
XX
AC AAX64642;
XX
DT 20-JUL-1999 (first entry)
XX
DE Human B7-1 hammerhead ribozyme target SEQ ID NO:1274.
XX
KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9618736-A2.
XX
PD 20-JUN-1996.
XX
PF 22-NOV-1995; 95WO-US15516.
XX
PR 05-OCT-1995; 95US-0541365.
PR 13-DEC-1994; 94US-0354920.
PR 23-DEC-1994; 94US-0363253.
PR 23-DEC-1994; 94US-0363254.
PR 17-FEB-1995; 95US-0390850.
PR 20-APR-1995; 95US-0426124.
PR 02-MAY-1995; 95US-0432874.
PR 04-MAY-1995; 95US-0434509.
PR 07-JUL-1995; 95US-0000951.
PR 07-JUL-1995; 95US-0000974.
PR 07-AUG-1995; 95US-0512861.
XX
PA (RIBO) RIBOZYME PHARM INC.
XX
PI Draper K, Castelhano J, McSwiggen J, Baron B, Stinchcomb DT;
PI Rothjeman L, Karpeisky A, Modak A, Usman N, Burgin A;

PT Matulic-Adamic J, Jarvis T, Thompson JD, Wincott F;
XX
DR WPI; 1996-309654/30.
XX
PT Enzymatic nucleic acid molecules having a hammerhead motif - used
PT for the treatment of arthritis, induction of graft tolerance or
PT treatment of auto immune diseases
XX
PS Claim 10; Page 167; 307pp; English.
XX
CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
CC at least ten 2' O-methyl modifications, and (iv) a 3' end modification.
CC The ENA's can inhibit collagenase and stromelysin production in the
CC synovial membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention.
XX
SQ Sequence 15 BP; 6 A; 3 C; 2 G; 4 U; 0 other;

Query Match 42.9%; Score 6; DB 17; Length 15;
Best Local Similarity 42.9%; Pred. No. 8.1e-04;
Matches 6; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttgnnnnnnnnnq 14
|||| ||
Db 15 TTTGACTGATAACG 2

RESULT 6
AAX56323/c
ID AAX56323 standard; DNA; 15 BP.
XX
AC AAX56323;
XX
DT 21-JUL-1999 (first entry)
XX
DE Neisseria gonorrhoeae detection primer GCIR-BL5.1.
XX
KW Neisseria gonorrhoeae; thermophilic strand displacement amplification;
KW homogeneous fluorescent real time tSDA; detection; amplification;
KW primer; tSDA; PCR; 3SR; transcription-mediated amplification; NASBA; ss.
XX
OS Synthetic.
OS Neisseria gonorrhoeae.
XX
PN EP919633-A2.
XX
PD 02-JUN-1999.
XX
PF 03-NOV-1998; 98EP-0120807.
XX
PR 04-NOV-1997; 97US-0963946.
XX
PA (BECT) BECTON DICKINSON & CO.
XX
PI Diffi Yanson K, Dermowicz SP, Harris JM;
XX
DR WPI; 1999-304828/26.
XX
PT New primers specific for Neisseria gonorrhoeae useful for detecting
PT this bacteria in a sample from a patient
XX
PS Claim 3; Page 31; 44pp; English.
XX
CC AAX56317 to AAX56355 represent oligonucleotide primers used in the
CC detection of Neisseria gonorrhoeae. The primers may be used to detect the
CC presence of Neisseria gonorrhoeae in a sample from a patient using
CC thermophilic Strand Displacement Amplification (tSDA) or homogeneous
CC fluorescent real time tSDA using dye donor/acceptor pairs. Alternatively
CC they may used as signal primers in other amplification methods such as
CC PCR, 3SR, Transcription-mediated amplification or NASBA. These methods
CC are used to discriminate between the nucleic acids of Neisseria
CC gonorrhoeae and those of other species of bacteria. The oligonucleotides
CC may also be employed before or after culture of Neisseria gonorrhoeae to
CC confirm its identity. Prior art methods of detecting Neisseria
CC gonorrhoeae involved overnight culture of clinical swabs followed by
CC biochemical and/or microscopic identification. The oligonucleotides are
CC designed against sequence specific regions of Neisseria gonorrhoeae DNA
CC so they can distinguish this species in a sample that may contain other
CC Neisseria species of bacteria. In addition the oligonucleotides and
CC detection kits allow rapid identification of the bacteria without having
CC to resort to the time-consuming prior art methods.
XX
SQ Sequence 15 BP; 7 A; 4 C; 2 G; 2 T; 0 other;

Query Match 42.9%; Score 6; DB 20; Length 15;
Best Local Similarity 42.9%; Pred. No. 8.1e-04;
Matches 6; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttgnnnnnnnnnq 14
|||| ||
Db 14 TTTGATGATTGCG 1

RESULT 7
AAX30272/c
ID AAX30272 standard; DNA; 15 BP.
XX
AC AAX30272;
XX
DT 21-JUN-1999 (first entry)
XX
DE Neisseria gonorrhoeae target bumper primer GCIR-BL5.1.
XX
KW HIV; gag; bumper primer; amplification primer; probe; detection;
KW fluorescence quenching; Chlamydia trachomatis; Neisseria gonorrhoeae;
KW human; placental DNA; pathogen; ss.
XX
OS Synthetic.
XX
PN EP915173-A2.
XX
PD 12-MAY-1999.
XX
PF 03-NOV-1998; 98EP-0120832.
XX
PR 04-NOV-1997; 97US-0964020.
XX
PA (BECT) BECTON DICKINSON & CO.
XX
PI Little MC, Vonk GP;
XX
DR WPI; 1999-265944/23.
XX
PT New method for real time fluorescence-detection assays useful for
PT detecting nucleic acids from pathogens in samples from patients
XX
PS Example 5; Page 10; 16pp; English.
XX
CC The present invention describes a kit for conducting a fluorescence
CC detection assay to determine the presence, absence or amount of a target
CC analyte in a sample. The method and kit may be used to detect

CC amplification of nucleic acid molecules in real time using fluorescence
CC quenching for example. The assays may be used to detect the presence of
CC nucleic acids from pathogens in samples of body fluid from patients.
CC The kit allows a homogeneous nucleic acid amplification and real time
CC nucleic acid probe detection assay to be carried out with minimal
CC complexity which yields a consistent reliable fluorescent detection
CC signal. The present sequence represents a primer used in the
CC exemplification of the present invention.
XX
SQ Sequence 15 BP; 7 A; 4 C; 2 G; 2 T; 0 other;

Query Match 42.9%; Score 6; DB 20; Length 15;
Best Local Similarity 42.9%; Pred. No. 8.1e+04;
Matches 6; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttgnnnnnnnnncg 14
|||| ||
Db 14 TTTGATGATTTGCG 1

RESULT 8
AAZ59897
ID AAZ59897 standard; DNA; 15 BP.
XX
AC AAZ59897;
XX
DT 08-MAY-2000 (first entry)
XX
DE Consensus adenovirus minimal packaging element (A repeat)
XX
KW Adenovirus; minimal packaging element; A repeat; repressor binding site;
KW DNA delivery; ds.
XX
OS Mastadenovirus.
XX
PN WO9953085-A2.
XX
PD 21-OCT-1999.
XX
PF 15-APR-1999; 99WO-US08294
XX
PR 15-APR-1998; 98US-0081867.
PR 05-JUN-1998; 98US-0088321
XX
PA (UYNY) UNIV NEW YORK STATE RES FOUND.
XX
PI Hearing P, Schmid SI, Ostapchuk PH, Pettuck P;
XX
DR WPI; 2000-052657/04
XX
PT Regulating adenoviral packaging by incorporation of repressor binding
PT sites that allow selective suppression of packaging, used for gene
PT therapy -
XX
PS Disclosure; Page 15; 71pp; English.
XX
CC The invention relates to the regulation of adenoviral packaging.
CC The method of the invention comprises propagating an adenoviral
CC vector containing a repressor binding site, in the absence of its
CC repressor. After propagation, vector packaging is repressed by the
CC appropriate repressor protein. The invention also encompasses an
CC adenoviral vector that includes an adenoviral packaging sequence
CC containing several COUP-TF (chicken ovalbumin upstream promoter
CC transcription factor) binding sites (AAZ59896). Adenoviral vectors
CC containing repressor binding sites are used for DNA delivery, e.g., for
CC expression of a therapeutic protein, in genetic immunisation or to
CC produce antiviral DNA or antisense RNA. Typical therapeutic genes that
CC can be expressed include those for interleukin 2, alpha1-antitrypsin,
CC cystic fibrosis transmembrane conductance regulator and coagulation
CC factor VIII. These vectors have very large capacity (up to 36 kB) for
CC foreign DNA and minimise the risk of generating replication competent
CC virus (since vector and helper virus can be designed such that they
CC have no overlapping packaging sequences that might permit homologous
CC recombination). The presence of the repressor binding site allows
CC selective inhibition of virion production (i.e., packaging of the vector
CC in presence of another). Sequences AAZ59890 Z59896 represent adenovirus
CC minimal packaging elements, designated A repeats A1 AV11, and AAZ59897
CC represents a consensus of these A repeats.
XX
SQ Sequence 15 BP; 1 A; 1 C; 2 G; 3 T; 8 other;

Query Match 42.9%; Score 6; DB 21; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.1e+04;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 tttgnnnnnnnnncg 14
||||||||||||||
Db 2 tttgnnnnnnnnncg 15

RESULT 9
AAZ62723/c
ID AAZ62723 standard; RNA; 15 BP
XX
AC AAZ62723;
XX
DT 28-MAR-2000 (first entry)
XX
DE Substrate for HH ribozyme HCV 6413 which cleaves HCV RNA at nt. 6413.
XX
KW Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW autoimmune disease; ss.
XX
OS Hepatitis C virus.
XX
PN WO9955847-A2.
XX
PD 04-NOV-1999.
XX
PF 26-APR-1999; 99WO-US09027.
XX
PR 27-APR-1998; 98US-0083217.
PR 18-SEP-1998; 98US-0100842.
PR 25-FEB-1999; 99US-0257608.
PR 23-MAR-1999; 99US-0274553.
XX
PA (RIBO) RIBOZYME PHARM INC.
XX
PI Wick L, Mayfield JA, Beigelman L, Lewis IA, Marcusjak D;
XX
DR WPI; 2000-062021/05.
XX
PT Novel ribozymes for the treatment of diseases and conditions related to
PT hepatitis C infection -
XX
PS Claim 1; Page 61; 123pp; English.
XX
CC The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given
CC in the descriptor line.
CC The HCV sequence was screened for optimal ribozyme target sites using
CC a computer folding algorithm and regions of the mRNA which did not form
CC secondary folding structures and contained potential ribozyme cleavage
CC sites were identified. Ribozymes were synthesised to target these sites
CC and their activities optimised by either varying the length of the
CC binding arms or by modification to prevent degradation by nucleases.
CC The ribozymes of the invention inhibit gene expression and/or viral
CC replication, and are used to treat diseases associated with Hepatitis C
CC virus (HCV) infection, e.g. cirrhosis, liver failure and hepatocellular
CC carcinoma. The ribozymes may be used in combination with interferon to
CC treat HCV infection, other infectious diseases, autoimmune diseases, and
CC cancer.

```
XX
SQ   Sequence 15 BP; 6 A; 4 C; 3 G; 2 U; 0 other;


  Query Match             42.9%;  Score 6;  DB 21;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgaaaaaaaaaaq 14
           ||||         ||
Db      15 TTTGCATGAPGCCG 2


RESULT 10
AAF57499/c
ID   AAF57499 standard; DNA; 15 BP.
XX
AC   AAF57499;
XX
DT   11-JUN-2001  (first entry)
XX
DE   pBAD oprI vector amplifying primer.
XX
KW   Bacteriophage; pseudovirion; phagemid; pathogen; antibacterial;
KW   camel; oprI; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO200121817-A1.
XX
PD   29-MAR-2001.
XX
PF   22-SEP-2000; 2000WO-EP09277.
XX
PR   24-SEP-1999;   99EP-0402448.
PR   03-NOV-1999;   99US-0433404.
XX
PA   (VLAA ) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI   Muyldermans S,  Silence K,  Steyaert J,  Toreele E;
XX
DR   WPI; 2001-257995/26.
XX
PT   New genetically modified bacteriophage, pseudovirion or phagemid
PT   capable of entering host cell by binding of its artificial ligand to
PT   artificial receptor present on host cell, useful for eliminating
PT   specific bacterial population -
XX
PS   Example 11; Page 35; 69pp; English.
XX
CC   The invention provides a genetically modified bacteriophage, pseudovirion
CC   or phagemid (I) capable of entering a host cell by binding of its
CC   artificial ligand (AL) to an artificial receptor (AR) present on the host
CC   cell. (I) is useful for detecting and/or eliminating a specific bacterial
CC   population, by AR-AL interaction, and to screen an antigen and/or
CC   antibody library. (I) is useful for selecting AR-AL interactions. A kit
CC   comprising (I) is useful for simultaneous in vivo panning of antibody or
CC   antibody fragment library or antigenic sequences library. (I) is useful
CC   for specific elimination of pathogenic bacteria, e.g., Aeromonas,
CC   Enterococcus, Legionella, Listeria, Neisseria, etc and for screening a
CC   host cell, displaying a bait against a library of bacteriophages/
CC   pseudovirions/phagemids displaying the preys. The present sequence
CC   represents a PCR primer for amplifying the pBAD-oprI vector.
XX
SQ   Sequence 15 BP; 5 A; 6 C; 2 G; 2 T; 0 other;


  Query Match             42.9%;  Score 6;  DB 22;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgaaaaaaaaaaq 14
           ||||         ||
Db      14 TTTGTCGGTGAACG 1


RESULT 11
AAF46300/c
ID   AAF46300 standard; DNA; 15 BP.
XX
AC   AAF46300;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1139.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF 1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition, hyperplasia, kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU00693.
XX
PR   21-JUN-1999;   99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by
PT   administering UV (ultra-violet) treatment (optional) and an antisense
PT   nucleic acid that inhibits or reduces growth factor mediated cell
PT   proliferation and/or inflammation -
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-AAF45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor-mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 4 A; 9 C; 1 G; 2 T; 0 other;


  Query Match             42.9%;  Score 6;  DB 22;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgaaaaaaaaaaq 14
           ||||         ||
Db      15 TTTGGAGAGGGCCG 2
```

```
RESULT  12
AAF46301/c
ID   AAF46301 standard; DNA; 15 BP.
XX
AC   AAF46301;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1140.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP2; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer, sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU00693.
XX
PR   21-JUN-1999;   99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by
PI   administering UV (ultra-violet) treatment (optional) and an antisense
PT   nucleic acid that inhibits or reduces growth factor mediated cell
PT   proliferation and/or inflammation -
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF] 1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-F45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor-mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 3 A; 9 C; 1 G; 2 T; 0 other;


  Query Match             42.9%;  Score 6;  DB 22;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnncg 14
           ||||         ||
Db      14 TTTGGAGACGGGCG 1


RESULT  13
AAF47804/c
ID   AAF47804 standard; DNA; 15 BP.
XX
AC   AAF47804;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1224.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation, ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU00693.
XX
PR   21-JUN-1999;   99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by
PI   administering UV (ultra-violet) treatment (optional) and an antisense
PT   nucleic acid that inhibits or reduces growth factor mediated cell
PT   proliferation and/or inflammation -
XX
PS   Example 7; Page 52; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-F45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor-mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 4 A; 5 C; 1 G; 5 T; 0 other;


  Query Match             42.9%;  Score 6;  DB 22;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnncg 14
           ||||         ||
Db      15 TTTGATAGGAAGCG 2


RESULT  14
AAF47805/c
ID   AAF47805 standard; DNA; 15 BP.
XX
AC   AAF47805;
XX
```

```
ID   9  MAR 2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1225.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078441 A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;  99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ, Werther GA, Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PI   Ameliorating the effects of a disorder, e.g. psoriasis, by
PI   administering UV (ultra violet) treatment (optional) and an antisense
PI   nucleic acid that inhibits or reduces growth factor mediated cell
PI   proliferation and/or inflammation -
XX
PS   Example 7; Page 52; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-F45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloide,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 5 A; 5 C; 1 G; 4 T; 0 other;

  Query Match          42.9%;  Score 6;  DB 22;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e-4;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 TTTAAAAAAAAAAAA 14
             |||:          |
Db      14 TTTGATACGAAGGG 1

RESULT 15
AAF45095
ID   AAF45095 standard; DNA; 15 BP.
XX
AC   AAF45095;
XX
DT   9-MAR-2001  (first entry)
XX
DE   IGF-1 oligonucleotide #895.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078441 A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;  99US-0140345.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ, Werther GA, Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PI   Ameliorating the effects of a disorder, e.g. psoriasis, by
PI   administering UV (ultra violet) treatment (optional) and an antisense
PI   nucleic acid that inhibits or reduces growth factor mediated cell
PI   proliferation and/or inflammation
XX
PS   Example 8; Page 66; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects
CC   of skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin like Growth Factor [IGF] 1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and
CC   AAF45153-F45161). The method is useful for ameliorating the effects of
CC   psoriasis, ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids,
CC   keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC   skin, a hyperneovascular condition such as a neovascular condition of the
CC   retina, brain or skin, growth factor-mediated malignancies, other
CC   sclerotic disease, kidney disease, hyperproliferation of the inside of
CC   blood vessels or any other hyperplasia.
XX
SQ   Sequence 15 BP; 1 A; 2 C; 8 G; 4 T; 0 other;

  Query Match          42.9%;  Score 6;  DB 22;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 8.1e-4;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 TTTAAAAAAAAAAAA 14
             |||:          ||
Db       2 TTTGATTCGTTCCCT 15


Search completed: September  4, 2002, 21:54:24
Job time: 13372 sec
```

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run On: September 3, 2002, 22:51:47 ; Search time 42.9 Seconds
(without alignments)
80.160 Million cell updates/sec

Title: US-09-530-935-1
Perfect score: 14
Sequence: 1 tttgnnnnnnnnnnc 14

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/2/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/2/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/2/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/2/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/2/ina/backfile1.seq:*
6: /cgn2_6/ptodata/2/ina/backfile2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
c 1	6	42.9	15	1	US-08-182-968A-334	Sequence 334, App
c 2	6	42.9	15	2	US-08-774-206A-334	Sequence 334, App
c 3	6	42.9	15	2	US-08-[illegible]	Sequence 1[illegible], App
c 4	6	42.9	15	2	US-08-963-946-11	Sequence 11, Appl
c 5	6	42.9	15	3	US-08-964-020-13	Sequence 13, Appl
c 6	6	42.9	15	3	US-08-964-156A-334	Sequence 334, App
c 7	6	42.9	15	4	US-09-038-073-136	Sequence 136, App
8 6 42.9 17 1 US-08-373-124A-1212 Sequence 1212, Ap
9 6 42.9 17 1 US-08-435-628-1212 Sequence 1212, Ap
c 10 6 42.9 17 2 US-08-[illegible] Sequence 1664, Ap
c 11 6 42.9 17 2 US-08-[illegible] Sequence 1829, Ap
c 12 6 42.9 17 2 US-08-292-620A-1906 Sequence 1906, Ap
13 6 42.9 17 2 US-08-989-706-32 Sequence 32, Appl
c 14 6 42.9 17 3 US-09-071-845-1664 Sequence 1664, Ap
c 15 6 42.9 17 3 US-09-071-845-1829 Sequence 1829, Ap
c 16 6 42.9 17 3 US-09-071-845-1906 Sequence 1906, Ap
17 6 42.9 17 4 US-08-584-040-1996 Sequence 1996, Ap
18 6 42.9 17 4 US-08-584-040-4222 Sequence 4222, Ap
c 19 6 42.9 17 4 US-08-584-040-5503 Sequence 5503, Ap
c 20 6 42.9 17 4 US-08-584-040-5504 Sequence 5504, Ap
21 6 42.9 18 1 US-08-379-081B-228 Sequence 228, App
22 6 42.9 18 1 US-09-379-081B-229 Sequence 229, App
23 6 42.9 18 1 US-08-379-078-228 Sequence 228, App
24 6 42.9 18 1 US-08-379-078-229 Sequence 229, App
c 25 6 42.9 18 1 US-08-379-836B-30 Sequence 30, Appl
26 6 42.9 18 3 US-09-138-024-14 Sequence 14, Appl
c 27 6 42.9 18 3 US-09-[illegible] Sequence [illegible], Appl
c 28 6 42.9 18 4 US-09-193-277B-42 Sequence 42, Appl
c 29 6 42.9 18 5 PCT-US95-13142-30 Sequence 30, Appl
c 30 6 42.9 19 1 US-08-093-144-14 Sequence 14, Appl
c 31 6 42.9 19 2 US-09-031-442A-12 Sequence 12, Appl
c 32 6 42.9 19 2 US-08-598-607-4 Sequence 4, Appli
c 33 6 42.9 19 4 US-09-081-576-6 Sequence 6, Appli
c 34 6 42.9 19 4 US-09-384-305-12 Sequence 12, Appl
c 35 6 42.9 19 4 US-09-258-377-12 Sequence 12, Appl
c 36 6 42.9 19 4 US-08-274-606-5 Sequence 5, Appli
c 37 6 42.9 19 4 US-08-771-190-5 Sequence 5, Appli
c 38 6 42.9 19 4 US-09-189-294B-1 Sequence 1, Appli
c 39 6 42.9 19 4 US-09-189-294B-3 Sequence 3, Appli
40 6 42.9 19 4 US-09-189-294B-4 Sequence 4, Appli
c 41 6 42.9 19 5 PCT-US94-07955-5 Sequence 5, Appli
c 42 6 42.9 19 6 5290690-18 Patent No. 5290690
c 43 6 42.9 20 1 US-07-621-091C-10 Sequence 10, Appl
44 6 42.9 20 1 US-08-096-182A-14 Sequence 14, Appl
c 45 6 42.9 20 1 US-08-474-542A-94 Sequence 94, Appl

ALIGNMENTS

RESULT 1
US-08-182-968A-334/c
; Sequence 334, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: [illegible] Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13 JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14 MAY 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 225/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 334:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-182-968A-334

Query Match 42.9%; Score 6; DB 1; Length 15;
Best Local Similarity 42.9%; Pred. No. 1e+04;
Matches [illegible]; Conservative 0; Mismatches 8; Indels [illegible]; Gaps [illegible];

```
Qy       1 tttcnnnnnnnnnnc 14
           ||||         ||
Db      15 TTTCACTGATAAGG 2


RESULT   3
US-08-774-806A-334/c
; Sequence 334, Application US/08774806A
; Patent No. 5869253
;  GENERAL INFORMATION:
;     APPLICANT:  Draper, Kenneth G.
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR
;     TITLE OF INVENTION:  INHIBITING REPLICATION O
;     TITLE OF INVENTION:  VIRUS REPLICATION
;     NUMBER OF SEQUENCES:  397
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 MB
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/774,806A
;       FILING DATE:  December 26, 1996
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/182,968
;       FILING DATE:  January 13, 1994
;       APPLICATION NUMBER:  07/882,888
;       FILING DATE:  May 14, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  222/227
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955 0440
;       TELEX:  67 3510
;   INFORMATION FOR SEQ ID NO:  334:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-774-806A-334


  Query Match             42.9%;  Score 6;  DB 2;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttcnnnnnnnnnnc 14
           ||||         ||
Db      15 TTTCACTGATAAGG 2


RESULT   4
US-08-585-684B-136/c
; Sequence 136, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Daniel T.
;     APPLICANT:  Jarvis, Phil
;     APPLICANT:  McSwiggen, James
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;     TITLE OF INVENTION:  INHIBITION OF HUMAN PAPILLO
;     NUMBER OF SEQUENCES:  136
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Ribozyme
;       STREET:  950 West 14th Street
;       STREET:  Suite 17
;       CITY:  Boulder
;       STATE:  Colorado
;       COUNTRY:  U.S.A.
;       ZIP:  80302
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 MB
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/585,684B
;       FILING DATE:  January 16, 1996
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/182,968
;       FILING DATE:  July 7, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  223/278
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  136:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-585-684B-136


  Query Match             42.9%;  Score 6;  DB 2;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttcnnnnnnnnnnc 14
           ||||         ||
Db      15 TTTCACTGATAAGG 2


RESULT   4
US-08-963-946-11/c
; Sequence 11, Application US/08963946
; Patent No. 5962273
;  GENERAL INFORMATION:
;     APPLICANT:  Dunnwick, Gerard P.
;     APPLICANT:  Harris, James M.
;     APPLICANT:  Yanson, Karen D.
;     TITLE OF INVENTION:  Detection of Neisseria Gonorrhoeae by
;     TITLE OF INVENTION:  Amplification and Detection of Its Nucleic Acid
;     NUMBER OF SEQUENCES:  59
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Richard J. Rodrick  Beeton, Tuskinson and
;       ADDRESSEE:  Company
;       STREET:  1 Beeton Drive
;       CITY:  Franklin Lakes
;       STATE:  NJ
;       COUNTRY:  USA
;       ZIP:  07417
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC Compatible
;       OPERATING SYSTEM:  PC DOS/MS DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/963,946
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Highet, David W.
;      REGISTRATION NUMBER:  30,265
;      REFERENCE/DOCKET NUMBER:  P-3869
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (201) 847-5317
;      TELEFAX:  (201) 848-9228
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-963-946-11

  Query Match                 42.9%;  Score 6;  DB 2;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGATGATTTGCG 1


RESULT   5
US-08-964-020-13/c
; Sequence 13, Application US/08/964,020
; Patent No. 6077669
;  GENERAL INFORMATION:
;    APPLICANT:  Vonk, Glenn P.
;    APPLICANT:  Little, Michael C.
;    TITLE OF INVENTION:  Kit and Method for Fluorescence Based
;    TITLE OF INVENTION:  Detection Assay
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick  Becton, Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/964,020
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Highet, David W.
;      REGISTRATION NUMBER:  30,265
;      REFERENCE/DOCKET NUMBER:  P-4025
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (201) 847-5317
;      TELEFAX:  (201) 848-9228
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-964-020-13

  Query Match                 42.9%;  Score 6;  DB 3;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGATGATTTGCG 1


RESULT   6
US-09-064-156A-334/c
; Sequence 334, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/064,156A
;      FILING DATE:  April 21, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/774,306
;      FILING DATE:  December 26, 1996
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  244/083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1500
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  334:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-064-156A-334

  Query Match                 42.9%;  Score 6;  DB 3;  Length 15;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      15 TTTGCATGATGCCG 2


RESULT   7
US-09-038-073-136/c
; Sequence 136, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
```

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHODS AND REAGENT FOR THE
; TITLE OF INVENTION: INHIBITION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/[illegible]
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 213/3078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 136:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-136

Query Match 42.9%; Score 6; DB 4; Length 15;
Best Local Similarity 42.9%; Pred. No. 1e+04;
Matches 6; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttcnnnnnnnnnca 14
:|||: :||
Db 15 TTTGACTGATAACG 2

RESULT 8
US-08-473-124A-1212
; Sequence 1212, Application US/08473124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESISTANCE AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,94[illegible]
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/926,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: [illegible]
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1212:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-473-124A-1212

Query Match 42.9%; Score 6; DB 1; Length 17;
Best Local Similarity 21.4%; Pred. No. 1e+04;
Matches 3; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

Qy 1 tttcnnnnnnnnnca 14
:|||: :||
Db 1 TTTGACTGATAACG 14

RESULT 9
US-08-435-628-1212
; Sequence 1212, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESISTANCE AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:

```
;       APPLICATION NUMBER:  US/08/435,628
;       FILING DATE:  05-MAY-1995
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/373,124
;       FILING DATE:  January 13, 1995
;       APPLICATION NUMBER:  08/245,166
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1212:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-1212


  Query Match             42.9%;  Score 6;  DB 1;  Length 17;
  Best Local Similarity   21.4%;  Pred. No. 1e+04;
  Matches    3;  Conservative    3;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           :::|         ||
Db       1 UUUGAGAUAUGACG 14


RESULT  10
US-08-292-620A-1664/c
; Sequence 1664, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;     APPLICANT:  Susan Grimm
;     APPLICANT:  Dan T. Stinchcomb
;     APPLICANT:  James McSwiggen
;     APPLICANT:  Sean Sullivan
;     APPLICANT:  Kenneth G. Draper
;     TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;     TITLE OF INVENTION:  DISEASES OR CONDITIONS
;     TITLE OF INVENTION:  RELATED TO LEVELS OF
;     TITLE OF INVENTION:  INTRACELLULAR ADHESION
;     TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;     NUMBER OF SEQUENCES:  2390
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/292,620A
;       FILING DATE:  August 17, 1994
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;     PRIOR APPLICATION DATA:  including application
;     PRIOR APPLICATION DATA:  described below:                two
;       APPLICATION NUMBER:  08/008,895
;       FILING DATE:  January 19, 1993
;       APPLICATION NUMBER:  07/989,819
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1664:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-292-620A-1664


  Query Match             42.9%;  Score 6;  DB 2;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||         ||
Db      14 TTTGTGATCCTCCG 1


RESULT  11
US-08-292-620A-1829/c
; Sequence 1829, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;     APPLICANT:  Susan Grimm
;     APPLICANT:  Dan T. Stinchcomb
;     APPLICANT:  James McSwiggen
;     APPLICANT:  Sean Sullivan
;     APPLICANT:  Kenneth G. Draper
;     TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;     TITLE OF INVENTION:  DISEASES OR CONDITIONS
;     TITLE OF INVENTION:  RELATED TO LEVELS OF
;     TITLE OF INVENTION:  INTRACELLULAR ADHESION
;     TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;     NUMBER OF SEQUENCES:  2390
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071 2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/292,620A
;       FILING DATE:  August 17, 1994
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;     PRIOR APPLICATION DATA:  including application
;     PRIOR APPLICATION DATA:  described below:                two
;       APPLICATION NUMBER:  08/008,895
;       FILING DATE:  January 19, 1993
```

```
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  239/210
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1829:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-292-620A-1829

  Query Match             42.9%;  Score 6;  DB 2;  Length 17;
  Best Local Similarity   42.9%;  Prod. No. 1e-04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||          ||
Db      14 TTTGTGATCCTCCG 1


RESULT  12
US-08-292-620A-1906/c
; Sequence 1906, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;     APPLICANT:  Susan Grimm
;     APPLICANT:  Dan L. Stinchcomb
;     APPLICANT:  James McSwiggen
;     APPLICANT:  Sean Sullivan
;     APPLICANT:  Kenneth G. Draper
;     TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;     TITLE OF INVENTION:  DISEASES OR CONDITIONS
;     TITLE OF INVENTION:  RELATED TO LEVELS OF
;     TITLE OF INVENTION:  INTRACELLULAR ADHESION
;     TITLE OF INVENTION:  MOLECULE 1 (ICAM 1)
;     NUMBER OF SEQUENCES:  2906
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 6.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/xx2,222
;       FILING DATE:  August 17, 1994
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;     PRIOR APPLICATION DATA:  (including application
;     PRIOR APPLICATION DATA:  described below:                    Page
;       APPLICATION NUMBER:  08/008,805
;       FILING DATE:  January 22, 1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  239/210
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1906:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-292-620A-1906

  Query Match             42.9%;  Score 6;  DB 2;  Length 17;
  Best Local Similarity   42.9%;  Prod. No. 1e-04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttqnnnnnnnnnq 14
           ||||          ||
Db      14 TTTGTGATCCTCCG 1


RESULT  13
US-08-988-706-42
; Sequence 42, Application US/08988706
; Patent No. 6083698
;  GENERAL INFORMATION:
;     APPLICANT:  OLSEN, Sheri J.
;     APPLICANT:  ANGELLY, Tracy S.
;     APPLICANT:  LAWRENCE, Tammy
;     APPLICANT:  LESCALLEET, Jennifer L.
;     APPLICANT:  MURPHY, Patricia D.
;     APPLICANT:  ALLEN, Antoinette P.
;     APPLICANT:  SHROBER, Denise B.
;     APPLICANT:  WHITE, Marga B.
;     APPLICANT:  ZENG, Bin
;     APPLICANT:  SALZEWICZ, Lisa K.
;     TITLE OF INVENTION:  CANCER SUSCEPTIBILITY MUTATIONS OF BRCA1
;     NUMBER OF SEQUENCES:  55
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;       STREET:  3174 Porter Drive
;       CITY:  Palo Alto
;       STATE:  CA
;       COUNTRY:  USA
;       ZIP:  94304
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC Compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/988,706
;       FILING DATE:
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Lee, John E.
;       REGISTRATION NUMBER:  39,638
;       REFERENCE/DOCKET NUMBER:  PA-1158
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  650 208 1000
;       TELEFAX:  650-926-6123
;   INFORMATION FOR SEQ ID NO:  42:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc= "PCR"
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
;     FRAGMENT TYPE:  internal
```

```
;     ORIGINAL SOURCE:
;       ORGANISM:  HOMO SAPIENS
;       STRAIN:  BRCA1
US-08-988-706-32


  Query Match             42.9%;  Score 6;  DB 3;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnncg 14
           ||||          ||
Db       2 ITTGTGTGTGAACG 15


RESULT  14
US-09-071-845-1664/c
; Sequence 1664, Application Us/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;     APPLICANT:  Susan Grimm
;     APPLICANT:  Dan T. Stinchcomb
;     APPLICANT:  James McSwiggen
;     APPLICANT:  Sean Sullivan
;     APPLICANT:  Kenneth G. Draper
;     TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;     TITLE OF INVENTION:  DISEASES OR CONDITIONS
;     TITLE OF INVENTION:  RELATED TO LEVELS OF
;     TITLE OF INVENTION:  INTRACELLULAR ADHESION
;     TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;     NUMBER OF SEQUENCES:  2390
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/071,845
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/292,620
;       FILING DATE:  August 17, 1994
;       APPLICATION NUMBER:  08/008,895
;       FILING DATE:  January 19, 1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1664:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-071-845-1664


  Query Match             42.9%;  Score 6;  DB 3;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnncg 14
           ||||          ||
Db      14 TTTGTGATCCTCCG 1


RESULT  15
US-09-071-845-1829/c
; Sequence 1829, Application Us/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;     APPLICANT:  Susan Grimm
;     APPLICANT:  Dan T. Stinchcomb
;     APPLICANT:  James McSwiggen
;     APPLICANT:  Sean Sullivan
;     APPLICANT:  Kenneth G. Draper
;     TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;     TITLE OF INVENTION:  DISEASES OR CONDITIONS
;     TITLE OF INVENTION:  RELATED TO LEVELS OF
;     TITLE OF INVENTION:  INTRACELLULAR ADHESION
;     TITLE OF INVENTION:  MOLECULE 1 (I CAM-1)
;     NUMBER OF SEQUENCES:  2390
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/071,845
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/292,620
;       FILING DATE:  August 17, 1994
;       APPLICATION NUMBER:  08/008,895
;       FILING DATE:  January 19, 1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1829:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-071-845-1829


  Query Match             42.9%;  Score 6;  DB 3;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 1e+04;
  Matches    6;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1 tttgnnnnnnnnnncg 14
           ||||          ||
```

RESULT 1 US_11GGGATCCTGG_1

Search completed: September 3, 2002, 23:59:29
Job time: 3642 sec